Media ReleasesChimeric Therapeutics

View All Chimeric Therapeutics News

Chimeric Therapeutics - CLTX CAR T data shows regional control of tumour recurrence

• CLTX CAR T clinical data highlighted in Keynote presentation on November 20th
• 75% disease control rate seen at lowest dose level with up to 8 weeks of durability
• Tumour recurrence prevented at sites where CLTX CAR T cells were infused while tumour recurrence occurred at sites without CLTX CAR T cell infusion
• CLTX CAR T was generally well tolerated with no dose limiting toxicities and no observed cytokine release syndrome (CRS)
• MMP2 expression confirmed as central to CLTX CAR T tumour recognition and killing
• Positive preclinical evaluation of melanoma advances CLTX CAR T towards next phase 1 clinical trial
• Webinar to be held at 11:30am AEDT today to discuss further. Click here to register.

Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and the ASX leader in cell therapy, is pleased to highlight key additional data released with the final presentation of two CLTX CAR T abstracts at the Society for Neuro-Oncology (SNO) 26th annual scientific meeting.

Abstract CTIM-29, “Clinical evaluation of chlorotoxin-directed CAR T cells for patients with recurrent glioblastoma” provides insight into the initial clinical data for CLTX while abstract EXTH-10, “Exploration of a novel toxin-incorporating CAR T cell: how does chlorotoxin recognize glioblastoma cells?” expands on the translational understanding of Chlorotoxin (CLTX) activity.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.